3 documents found, page 1 of 1
Sulfated small molecules targeting EBV in Burkitt lymphoma: from in silico scre...
Lima, Raquel T.; Seca, Hugo; Palmeira, Andreia; Fernandes, Miguel X.; Castro, Felipe; Correia-da-Silva, Marta; Nascimento, Maria S. J.; Sousa, EmíliaEpstein–Barr virus (EBV) infects more than 90% of the world population. Following primary infection, Epstein– Barr virus persists in an asymptomatic latent state. Occasionally, it may switch to lytic infection. Latent EBV infection has been associated with several diseases, such as Burkitt lymphoma (BL). To date, there are no available drugs to target latent EBV, and the existing broad-spec trum antiviral drugs...
Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone
Palmeira, Andreia; Paiva, Ana; Sousa, Emília; Seca, Hugo; Almeida, Gabriela M.; Lima, Raquel T.; Fernandes, Miguel X.; Pinto, MadalenaNaturally occurring xanthones have been docu mented as having antitumor properties, with some of them presently undergoing clinical trials. In an attempt to improve the biological activities of dihydroxyxanthones, prenylation and other mole cular modifications were performed. All the com pounds reduced viable cell number in a leukemia cell line K-562, with the fused xanthone 3, 4-dihydro-12-hydroxy-2,2-dimethyl...
Proliferation and survival molecules implicated in the inhibition of BRAF pathw...
Preto, Ana; Gonçalves, Joana; Rebocho, Ana P; Figueiredo, Joana; Meireles, Ana M; Rocha, Ana S; Vasconcelos, Helena M; Seca, Hugo; Seruca, RaquelThyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The possibility of using inhibitors on the BRAF pathway as became an interesting therapeutic approach. In thyroid cancer cells the target molecules, implicated on the cellular effects, mediated by inhibition of BRAF are not well established. In order to fill this l...